Ausgabe 4/2014
Inhalt (23 Artikel)
Therapy resistance mechanisms in Ewing’s sarcoma family tumors
Atif A. Ahmed, Hamid Zia, Lars Wagner
A prospective phase II trial of S-1 and cisplatin-based chemoradiotherapy for locoregionally advanced esophageal cancer
Hyun Chang, Sung Kwan Shin, Byoung Chul Cho, Chang-Geol Lee, Choong Bai Kim, Dae Joon Kim, Jin Gu Lee, Jin Hur, Chang Young Lee, Mi Kyung Bae, Hye Ryun Kim, Sang Kil Lee, Jun Chul Park, Hyuk Lee, Hyoung-Il Kim, Hyunsoo Chung, Jihye Cha, Yong Chan Lee, Joo-Hang Kim
Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors
Megumi Inada-Inoue, Yuichi Ando, Kenji Kawada, Ayako Mitsuma, Masataka Sawaki, Taro Yokoyama, Yu Sunakawa, Hiroo Ishida, Kazuhiro Araki, Keishi Yamashita, Keiko Mizuno, Fumio Nagashima, Akiko Takekura, Kazuo Nagamatsu, Yasutsuna Sasaki
Elimination of EGFR-expressing circulating tumor cells in patients with metastatic breast cancer treated with gefitinib
Antonia Kalykaki, Sofia Agelaki, Galatea Kallergi, Alexandros Xyrafas, Dimitris Mavroudis, Vassilis Georgoulias
Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial
Carlos R. Becerra, Ramon Salazar, Rocio Garcia-Carbonero, Anne L. Thomas, Federico J. Vázquez-Mazón, James Cassidy, Tim Maughan, Manuel Gallén Castillo, Tim Iveson, Donghua Yin, Stephanie Green, Emily K. Bergsland
Phase I dose-escalation and pharmacokinetic study (TED 11576) of cabazitaxel in Japanese patients with castration-resistant prostate cancer
Hirofumi Mukai, Shunji Takahashi, Masahiro Nozawa, Yusuke Onozawa, Jun Miyazaki, Keiji Ohno, Kazuhiro Suzuki
Perifosine inhibits S6K1–Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency
Ying Xin, Xiang-di Shen, Long Cheng, De-fei Hong, Bin Chen
Clinical pharmacokinetics of Icotinib, an anti-cancer drug: evaluation of dose proportionality, food effect, and tolerability in healthy subjects
Dongyang Liu, Ji Jiang, Li Zhang, Fenlai Tan, Yingxiang Wang, Don Zhang, Pei Hu
Combination antiretroviral therapy (cART) component ritonavir significantly alters docetaxel exposure
Michelle A. Rudek, Cathy Y. Chang, Kenneth Steadman, Michael D. Johnson, Naveen Desai, John F. Deeken
Population pharmacokinetics and exposure–response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer
Valérie F. Cosson, Vivian W. Ng, Michaela Lehle, Bert L. Lum
Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS
Tomokazu Kishiki, Hiroaki Ohnishi, Tadahiko Masaki, Kouki Ohtsuka, Yasuo Ohkura, Jyunji Furuse, Takashi Watanabe, Masanori Sugiyama
Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors
Matthias Freiwald, Ulrike Schmid, Angele Fleury, Sven Wind, Peter Stopfer, Alexander Staab
BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy
Mathilde Foedermayr, Miriam Sebesta, Margaretha Rudas, Anna S. Berghoff, Regina Promberger, Matthias Preusser, Peter Dubsky, Florian Fitzal, Michael Gnant, Guenther G. Steger, Ansgar Weltermann, Christoph C. Zielinski, Otto Zach, Rupert Bartsch
Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients
Fei-fei Han, Chang-long Guo, Dan Yu, Jin Zhu, Li-li Gong, Guang-run Li, Ya-li Lv, He Liu, Guang-yu An, Li-hong Liu
Pharmacokinetics of doxorubicin in pregnant women
Rachel J. Ryu, Sara Eyal, Henry G. Kaplan, Arezoo Akbarzadeh, Karen Hays, Kristin Puhl, Thomas R. Easterling, Stacey L. Berg, Kathleen A. Scorsone, Eric M. Feldman, Jason G. Umans, Menachem Miodovnik, Mary F. Hebert
A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer
Yee Chao, Jan-Sing Hsieh, Hsien-Tang Yeh, Yu-Chieh Su, Cheng-Chung Wu, Jen-Shi Chen, Cheng-Jeng Tai, Li-Yuan Bai, Kun-Huei Yeh, Wu-Chou Su, Chung-Pin Li
Paris Saponin II suppresses the growth of human ovarian cancer xenografts via modulating VEGF-mediated angiogenesis and tumor cell migration
Xue Xiao, Mei Yang, Jianguo Xiao, Juan Zou, Qin Huang, Kaixuan Yang, Bo Zhang, Fan Yang, Shanling Liu, He Wang, Peng Bai
Salvage chemotherapy with docetaxel and pegylated liposomal doxorubicin in pretreated patients with platinum- and taxane-sensitive ovarian cancer: a multicenter phase II trial of the Hellenic Oncology Research Group (HORG)
Filippos Koinis, Aristidis Polyzos, Athina Christopoulou, Zafeiris Zafeiriou, Christos Emmanouilidis, Elisavet Papadimitraki, Antonia Kalykaki, Kostas Kalbakis, George Samonis, Vassilis Georgoulias
Simvastatin suppresses head and neck squamous cell carcinoma ex vivo and enhances the cytostatic effects of chemotherapeutics
Matthaeus Stoehr, Christian Mozet, Andreas Boehm, Achim Aigner, Andreas Dietz, Gunnar Wichmann
A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere
Heloisa P. Soares, Soley Bayraktar, Marcelo Blaya, Gilberto Lopes, Jaime Merchan, Jessica Macintyre, Carlos Mayo, Mark R. Green, Orlando Silva, Joe Levi, Gail Walker, Caio M. Rocha-Lima
The impact of dose/time modification in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer
Goro Nakayama, Chie Tanaka, Keisuke Uehara, Naoki Mashita, Naomi Hayashi, Daisuke Kobayashi, Mitsuro Kanda, Suguru Yamada, Tsutomu Fujii, Hiroyuki Sugimoto, Masahiko Koike, Shuji Nomoto, Michitaka Fujiwara, Yuich Ando, Yasuhiro Kodera
Phase II clinical trial of PM00104 (Zalypsis®) in urothelial carcinoma patients progressing after first-line platinum-based regimen
Daniel E. Castellano, Joaquim Bellmunt, José Pablo Maroto, Albert Font-Pous, Rafael Morales-Barrera, Ismael Ghanem, Cristina Suarez, Cristina Martín Lorente, Olatz Etxaniz, Laia Capdevila, Cinthya Coronado, Vicente Alfaro, Mariano Siguero, Carlos Fernández-Teruel, Joan Carles
The interactions of lenalidomide with human uptake and efflux transporters and UDP-glucuronosyltransferase 1A1: lack of potential for drug–drug interactions
Zeen Tong, Usha Yerramilli, Sekhar Surapaneni, Gondi Kumar